cd8-guided il-2 fusion protein azd6750
Generic: CD8-guided IL-2 Fusion Protein AZD6750
cd8-guided il-2 fusion protein azd6750: 1 clinical trial tracked.
cd8-guided il-2 fusion protein azd6750 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about cd8-guided il-2 fusion protein azd6750, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Clinical Trials (1)
A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors
Primary endpoint: Safety- Part 1A & Part 2A (dose escalation) and Part 2B (dose expansion)
Interventionalopen60 targetStarted 2025-07Completion 2029-1013 sites · Australia, Japan, South Korea, United StatesAstraZeneca